-
Presenter Profile: Pharmacotherapy Considerations
Elena Toschi, MD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Friday, June 5, at 3:45 p.m. CT.
-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
-
Researchers to reveal trial results for dual agonism in type 1 diabetes
Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes.
-
Panel discussion to track diabetes across diverse populations in the U.S.
Jithin Sam Varghese, PhD, MTech, and other panelists will delve into the epidemiology of diabetes, social roadblocks, and variations in health outcomes across the country amid changing national demographics.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Experts to discuss AIDING results for automated insulin delivery in the hospital
Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
-
Panel discussion to explore stem cell-derived beta cell therapy for type 1 diabetes
Sanjoy Dutta, PhD, Jay Skyler, MD, and other panelists will share insights on advances in the use of manufactured islets and what it might take to achieve widespread clinical use.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.